Brainsway Q1 Earnings Call Highlights

Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base.

MarketBeat • 8 hours ago

BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights

R evenue grew approximately   35 % y ear- o ver- y ear to   $1 5 .5 million  for Q1 2026

GlobeNewsWire • 11 hours ago

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

Seeking Alpha • 7 hours ago

Are Medical Stocks Lagging Brainsway (BWAY) This Year?

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

Zacks Investment Research • May 4, 2026

BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026

BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its first quarter 2026 financial results and recent operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

GlobeNewsWire • Apr 29, 2026

Recent Price Trend in Brainsway (BWAY) is Your Friend, Here's Why

Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Investment Research • Apr 29, 2026

4 Medical Product Stocks to Buy From a Challenging Industry

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

Zacks Investment Research • Apr 27, 2026

BrainsWay: Competitive Threats Are Mounting

BrainsWay continues to deliver strong growth and margin improvement, supported by investments in TMS service providers and recurring revenue expansion. BWAY's accelerated protocol and expanded indications, including adolescent depression, are supportive of further growth. TMS is a relatively expensive treatment option though with a high patient burden, making the impeding entry of psychedelics (psilocybin, LSD, DMT) into the market a serious threat.

Seeking Alpha • Apr 24, 2026

BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments

GlobeNewsWire • Apr 15, 2026

BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026.

GlobeNewsWire • Apr 13, 2026